Physician profile
Davis Co Chu
NPI 1205842796
$455.49
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $87.02 · 2021: $114 · 2022: $68.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $101.90 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $85.49 | 2020-2022 | |
| Pfizer INC. | $51.90 | 2019-2021 | |
| Novo Nordisk INC | $36.03 | 2021 | |
| Genentech USA, INC. | $35.05 | 2019 | |
| Glaxosmithkline, LLC. | $29.19 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.69 | 2022 | |
| Amarin Pharma, INC. | $16.08 | 2020 | |
| Ethicon US, LLC | $15.76 | 2019 | |
| Lilly USA, LLC | $15.00 | 2020 | |
| Dexcom, INC. | $14.84 | 2021 | |
| Sanofi Pasteur INC. | $12.97 | 2022 | |
| Merck Sharp & Dohme LLC | $11.50 | 2019 | |
| Abbvie INC. | $11.09 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davis Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.